ABL2 Human shRNA Plasmid Kit (Locus ID 27)

Specifications

Product Data
Locus ID	27
Synonyms	ABLL; ARG; FLJ22224; FLJ31718; FLJ41441
Vector	pRS
E. coli Selection	Ampicillin
Mammalian Cell Selection	Puromycin
Format	Retroviral plasmids
Kit Components	ABL2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 27). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq	NM_001100108, NM_001136000, NM_001136001, NM_001168236, NM_001168237, NM_001168238, NM_001168239, NM_005158, NM_007314, NM_007314.1, NM_007314.2, NM_007314.3, NM_005158.1, NM_005158.2, NM_005158.3, NM_005158.4, NM_001136000.1, NM_001136000.2, NM_001136001.1, NM_001168239.1, NM_001168238.1, NM_001168237.1, NM_001168236.1, NM_001100108.1, BC065912, NM_001136000.3, NM_001168236.2, NM_005158.5, NM_001168237.2, NM_001168238.2, NM_001168239.2, NM_007314.4
UniProt ID	P42684
Summary	This gene encodes a member of the Abelson family of nonreceptor tyrosine protein kinases. The protein is highly similar to the c-abl oncogene 1 protein, including the tyrosine kinase, SH2 and SH3 domains, and it plays a role in cytoskeletal rearrangements through its C-terminal F-actin- and microtubule-binding sequences. This gene is expressed in both normal and tumor cells, and is involved in translocation with the ets variant 6 gene in leukemia. Multiple alternatively spliced transcript variants encoding different protein isoforms have been found for this gene. [provided by RefSeq, Nov 2009]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact tech@clinisciences.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at tech@clinisciences.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).